OTLK (Outlook Therapeutics Inc) dropped -8.56 at the last close: Is This Today’s Most Popular Stock?

Outlook Therapeutics Inc (NASDAQ: OTLK) kicked off on Tuesday, down -8.56% from the previous trading day, before settling in for the closing price of $1.87. Over the past 52 weeks, OTLK has traded in a range of $0.87-$12.85.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Healthcare Sector giant saw their annual sales slid by -20.00% over the last five years. While this was happening, its average annual earnings per share was recorded 52.49%. With a float of $23.59 million, this company’s outstanding shares have now reached $24.91 million.

The firm has a total of 23 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Outlook Therapeutics Inc (OTLK) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Outlook Therapeutics Inc is 26.33%, while institutional ownership is 14.44%. The most recent insider transaction that took place on Sep 26 ’24, was worth 28,446. In this transaction Chief Financial Officer of this company bought 5,000 shares at a rate of $5.69, taking the stock ownership to the 5,946 shares. Before that another transaction happened on Mar 28 ’24, when Company’s Director bought 1,882 for $11.82, making the entire transaction worth $22,242. This insider now owns 5,049 shares in total.

Outlook Therapeutics Inc (OTLK) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 52.49% per share during the next fiscal year.

Outlook Therapeutics Inc (NASDAQ: OTLK) Trading Performance Indicators

Take a look at Outlook Therapeutics Inc’s (OTLK) current performance indicators. Last quarter, stock had a quick ratio of 0.26.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.94, a number that is poised to hit -0.61 in the next quarter and is forecasted to reach -0.52 in one year’s time.

Technical Analysis of Outlook Therapeutics Inc (OTLK)

Analysing the last 5-days average volume posted by the [Outlook Therapeutics Inc, OTLK], we can find that recorded value of 0.57 million was lower than the volume posted last year of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 57.24%. Additionally, its Average True Range was 0.20.

During the past 100 days, Outlook Therapeutics Inc’s (OTLK) raw stochastic average was set at 13.75%, which indicates a significant decrease from 19.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.16% in the past 14 days, which was lower than the 186.57% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.8481, while its 200-day Moving Average is $5.5255. Now, the first resistance to watch is $1.8667. This is followed by the second major resistance level at $2.0233. The third major resistance level sits at $2.1667. If the price goes on to break the first support level at $1.5667, it is likely to go to the next support level at $1.4233. Now, if the price goes above the second support level, the third support stands at $1.2667.

Outlook Therapeutics Inc (NASDAQ: OTLK) Key Stats

The company with the Market Capitalisation of 54.75 million has total of 31,980K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -75,370 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was 5,690 K.